This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PDCO Q3 Earnings & Sales Miss Estimates, Margins Contract
by Zacks Equity Research
Patterson Companies' overall top-line figure for the third quarter of fiscal 2025 reflects weak segmental performance.
Amedisys (AMED) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -8.57% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Fresenius Medical Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
FMS' fourth-quarter results showcase a strong segmental performance along with providing full year 2025 outlook for revenue growth and operating income.
INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up
by Zacks Equity Research
Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.
Tempus Stock Falls as Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
BAX Stock Surges Following Q4 Earnings & Sales Beat, Margins Decline
by Zacks Equity Research
Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract. Shares rise in pre-market.
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
by Zacks Equity Research
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
Why Fast-paced Mover Aveanna (AVAH) Is a Great Choice for Value Investors
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Aveanna (AVAH) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Down -17.59% in 4 Weeks, Here's Why You Should You Buy the Dip in Aveanna (AVAH)
by Zacks Equity Research
Aveanna (AVAH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Aveanna (AVAH) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aveanna Healthcare (AVAH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 300% and 2.67%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Dentsply Sirona Shares Fall After Suspension of Byte Aligner Products
by Zacks Equity Research
XRAY suspends Byte Aligner sales, citing regulatory review with the FDA, shifting resources to bolster other business areas amid compliance efforts.
DexCom Q3 Earnings Beat Estimates on Sensor Growth, Stock Rises
by Zacks Equity Research
DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
New Strong Buy Stocks for October 25th
by Zacks Equity Research
KGC, ORLA, CVNA, CAVA and AVAH have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2024.
Talkspace Shares Decline Despite Partnership With Wisdo Health
by Zacks Equity Research
TALK collaborates with Wisdo Health to enhance mental health support for seniors, addressing loneliness and improving access to care for the 65+ community.
LifeMD Shares Decline Even After the Launch of Testosterone Therapy
by Zacks Equity Research
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.77% and 3.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Can DaVita Stock Continue Its Bull Run After Doubling in a Year?
by Indrajit Bandyopadhyay
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research
by Zacks Equity Research
PACB partners with NCCS to enhance cancer research using the Onso short-read platform and Revio long-read sequencing, advancing precision oncology in Singapore and Asia.
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Merit Medical Stock Gains 24.7% Year to Date: What's Behind the Rally?
by Zacks Equity Research
MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets.
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
by Zacks Equity Research
TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.